South Korea · Delayed Price · Currency is KRW Sage Therapeutics Statistics
Total Valuation
CellBion has a market cap or net worth of KRW 350.52 billion. The enterprise value is 323.33 billion.
| Market Cap | 350.52B |
| Enterprise Value | 323.33B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
CellBion has 12.82 million shares outstanding.
| Current Share Class | 12.82M |
| Shares Outstanding | 12.82M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 36.45% |
| Owned by Institutions (%) | 3.59% |
| Float | 8.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 136.49 |
| PB Ratio | 12.45 |
| P/TBV Ratio | 12.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -44.30 |
| EV / Sales | 125.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -58.14 |
Financial Position
The company has a current ratio of 23.82, with a Debt / Equity ratio of 0.09.
| Current Ratio | 23.82 |
| Quick Ratio | 23.30 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.48 |
| Interest Coverage | -61.87 |
Financial Efficiency
Return on equity (ROE) is -40.96% and return on invested capital (ROIC) is -22.86%.
| Return on Equity (ROE) | -40.96% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -22.86% |
| Return on Capital Employed (ROCE) | -22.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 22,211.40 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 62.18 |
| Average Volume (20 Days) | 224,024 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CellBion had revenue of KRW 2.57 billion and -7.30 billion in losses. Loss per share was -570.21.
| Revenue | 2.57B |
| Gross Profit | 1.00B |
| Operating Income | -7.32B |
| Pretax Income | -7.30B |
| Net Income | -7.30B |
| EBITDA | -6.68B |
| EBIT | -7.32B |
| Loss Per Share | -570.21 |
Balance Sheet
The company has 29.85 billion in cash and 2.65 billion in debt, giving a net cash position of 27.20 billion or 2,122.01 per share.
| Cash & Cash Equivalents | 29.85B |
| Total Debt | 2.65B |
| Net Cash | 27.20B |
| Net Cash Per Share | 2,122.01 |
| Equity (Book Value) | 28.14B |
| Book Value Per Share | 2,198.56 |
| Working Capital | 30.06B |
Cash Flow
In the last 12 months, operating cash flow was -5.35 billion and capital expenditures -210.94 million, giving a free cash flow of -5.56 billion.
| Operating Cash Flow | -5.35B |
| Capital Expenditures | -210.94M |
| Free Cash Flow | -5.56B |
| FCF Per Share | -433.94 |
Margins
Gross margin is 39.04%, with operating and profit margins of -285.19% and -284.22%.
| Gross Margin | 39.04% |
| Operating Margin | -285.19% |
| Pretax Margin | -284.22% |
| Profit Margin | -284.22% |
| EBITDA Margin | -260.02% |
| EBIT Margin | -285.19% |
| FCF Margin | n/a |
Dividends & Yields
CellBion does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -2.08% |
| FCF Yield | -1.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CellBion has an Altman Z-Score of 19.5 and a Piotroski F-Score of 2.
| Altman Z-Score | 19.5 |
| Piotroski F-Score | 2 |